Latest Fusion protein Stories
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically Improve Biologic Protein Expression in Mammalian Cell Lines Geneva, Switzerland
SAN DIEGO, Jan.
Reportbuyer.com just published a new market research report:
MarketResearchReports.Biz announces addition of new report “Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend” to its database.
A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield.
Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Library Can Improve Product Yield in Mammalian Cell Lines Geneva, Switzerland (PRWEB) May 29, 2013
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.